AnDiConBio
Jiaxing
About AnDiConBio
developer of respiratory anti-infection drugs, offering high-potential, low-risk products like new anti-influenza and oral anti-new coronavirus.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $27.6M
- Funding stage: Early Stage Venture
- Last round: Series A (Apr 2024)
- Website: andicon.cn
Industries & Categories
Biopharma, Pharmaceutical, Therapeutics
Canonical: https://fsome.com/organization/andiconbio-101437 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.